A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

N/ANo Longer AvailableNCT03265171

Prometic Biotherapeutics, Inc.

Overview

These are single-patient studies with repeat-dose administration of ProMetic Plasminogen IV infusion in one adult and one child with hypoplasminogenemia. These patients are under treatment to address wound healing and obstructions.

Study Type

EXPANDED_ACCESS

Conditions

Hypoplasminogenemia

Interventions

Plasminogen (Human)BIOLOGICAL

Eligibility

Sex: ALLMin age: 16 Months

Medical Language ↔ Plain English

Inclusion Criteria: * Patient has provided informed consent. * Patient has a diagnosis of compound homozygous Type 1 plasminogen deficiency as evidence by ligneous conjunctivitis since birth as well as involvement of the conjunctiva, nasopharynx, gingiva, tracheobronchial tree, gastrointestinal tract, and urinary tract. Exclusion Criteria: * Not applicable

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.